Eos Med Chem

Email Address


Phone Number


Our Location

Jl. Sunset Road No.815



Aripiprazole dimer, identified by the Chemical Abstracts Service (CAS) number 1797986-18-5, is a significant molecular entity within the realm of pharmaceuticals. Its molecular formula, C48H56C14N604, underscores its complex structure and underscores its potential for therapeutic applications. This article delves into the characteristics, properties, and potential applications of aripiprazole dimer.


Aripiprazole dimer’s chemical formula, C48H56C14N604, reveals its intricate structure, composed of carbon, hydrogen, chlorine, nitrogen, and oxygen atoms. The arrangement of these atoms within the molecule contributes to its pharmacological properties and behavior within biological systems. The dimeric nature of aripiprazole suggests its potential for enhanced stability and pharmacokinetic properties compared to its monomeric counterpart.



Aripiprazole dimer likely exhibits characteristics similar to aripiprazole monomer, which is a white to off-white crystalline powder. Its physical form may vary depending on its preparation method and formulation.

The compound’s solubility, melting point, and stability are crucial factors influencing its pharmaceutical formulation and administration.


Aripiprazole dimer’s chemical properties govern its interaction with biological targets and metabolic pathways within the body.

Understanding its reactivity, stability, and potential for degradation under various conditions is essential for ensuring its efficacy and safety in clinical use.


Aripiprazole dimer likely retains the pharmacological activity of the parent compound, aripiprazole. As an antipsychotic agent, aripiprazole exerts its therapeutic effects through partial agonism at dopamine D2 and serotonin 5-HT1A receptors, and antagonism at serotonin 5-HT2A receptors.

The dimeric form may offer advantages such as prolonged duration of action, improved bioavailability, or enhanced receptor binding affinity compared to the monomeric form.


The synthesis of aripiprazole dimer involves the coupling of two aripiprazole molecules through a suitable linker or functional group. Various synthetic routes may be explored to optimize the yield, purity, and scalability of the process. Precise control over reaction conditions and purification techniques are essential to obtain the desired product in high yield and purity.



Aripiprazole dimer holds promise as a potential drug candidate for the treatment of psychiatric disorders such as schizophrenia, bipolar disorder, and major depressive disorder.

Its dimeric structure may confer advantages such as improved pharmacokinetic properties, reduced dosing frequency, or enhanced therapeutic efficacy compared to existing monomeric formulations.


Aripiprazole dimer can serve as a building block for the development of novel pharmaceutical formulations, including extended-release formulations, combination therapies, or targeted drug delivery systems.

Formulation scientists can explore various dosage forms such as tablets, capsules, injections, or transdermal patches to optimize the drug’s therapeutic profile and patient compliance.


Aripiprazole dimer provides a valuable tool for researchers studying the structure-activity relationships of aripiprazole and related compounds.

Investigating its pharmacological properties, mechanism of action, and potential therapeutic applications can lead to the discovery of new drug candidates with improved efficacy and safety profiles.


The absorption of aripiprazole dimer is a critical aspect of its pharmacokinetic profile, influencing the onset and duration of its therapeutic effects. Like its monomeric counterpart, the dimeric form is likely absorbed primarily in the gastrointestinal tract following oral administration. Factors such as solubility, formulation, and gastrointestinal motility can affect the rate and extent of absorption. Formulation strategies such as the use of solubilizers or particle size reduction techniques may enhance the bioavailability of the compound.


Upon absorption, aripiprazole dimer enters systemic circulation and undergoes distribution to various tissues and organs throughout the body. The compound’s lipophilic nature enables it to penetrate the blood-brain barrier, allowing for central nervous system (CNS) penetration and exertion of its therapeutic effects. Distribution may also occur to peripheral tissues, where the compound may accumulate or undergo metabolism. Protein binding, particularly to albumin and alpha-1-acid glycoprotein, influences the extent of distribution and the fraction of the drug available for pharmacological activity.


Metabolic transformation plays a significant role in the elimination of aripiprazole dimer from the body. Hepatic metabolism, primarily mediated by cytochrome P450 enzymes, leads to the formation of metabolites with varying pharmacological activity. Aripiprazole undergoes dehydrogenation, hydroxylation, and N-dealkylation, yielding active metabolites such as dehydroaripiprazole. The dimeric form may exhibit similar metabolic pathways, although potential differences in metabolic stability or enzyme kinetics could influence the overall metabolic profile.


Following metabolism, aripiprazole dimer and its metabolites are excreted from the body primarily via renal and fecal routes. Renal excretion of unchanged drug and metabolites accounts for a significant portion of total clearance. Biliary excretion may also contribute to the elimination of the compound and its metabolites. The pharmacokinetic parameters of aripiprazole dimer, including clearance, half-life, and volume of distribution, are essential considerations in dosing regimen optimization and therapeutic monitoring.


Aripiprazole dimer’s pharmacokinetic profile may be subject to modulation by concomitant administration of other drugs that affect drug-metabolizing enzymes or drug transporters. Inhibitors or inducers of cytochrome P450 enzymes, particularly CYP3A4 and CYP2D6, can alter the metabolism of aripiprazole dimer, leading to changes in plasma concentrations and therapeutic efficacy. Drug interactions should be carefully considered when co-administering aripiprazole dimer with other medications to avoid adverse effects or therapeutic failure.


Aripiprazole dimer exerts its pharmacodynamic effects primarily through modulation of dopamine and serotonin neurotransmission in the central nervous system. As a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, the compound exhibits a unique mechanism of action compared to traditional antipsychotic agents. By exerting partial agonism, aripiprazole dimer acts as a stabilizer of dopaminergic and serotonergic activity, resulting in both agonistic and antagonistic effects depending on the endogenous neurotransmitter levels and receptor occupancy. This unique pharmacological profile contributes to its efficacy in treating symptoms of schizophrenia, bipolar disorder, and major depressive disorder.


Aripiprazole dimer’s binding affinity for dopamine and serotonin receptors plays a crucial role in its pharmacodynamic activity and therapeutic efficacy. The compound exhibits high affinity for dopamine D2 receptors, where it acts as a partial agonist, exerting stabilizing effects on dopaminergic neurotransmission. Additionally, aripiprazole dimer binds to serotonin 5-HT1A receptors, contributing to its anxiolytic and antidepressant properties. The balance between dopamine and serotonin receptor binding affinities influences the compound’s overall pharmacological profile and clinical effects.


By modulating dopamine and serotonin neurotransmission, aripiprazole dimer helps restore the balance of these neurotransmitters in the brain, which is disrupted in psychiatric disorders such as schizophrenia and bipolar disorder. Dopamine dysregulation is implicated in the pathophysiology of psychosis, while serotonin abnormalities are associated with mood disturbances and affective symptoms. Aripiprazole dimer’s unique ability to exert partial agonism at dopamine receptors and modulate serotonin activity contributes to its broad spectrum of therapeutic effects across different psychiatric conditions.


Emerging evidence suggests that aripiprazole dimer may influence neuroplasticity and synaptic function in addition to its effects on neurotransmitter systems. Preclinical studies have demonstrated that aripiprazole can enhance synaptic plasticity and promote neuronal survival in animal models of neurodegenerative diseases and mood disorders. These effects may be mediated by downstream signaling pathways and intracellular mechanisms that regulate neuronal connectivity, synaptic strength, and neuronal survival. Understanding the impact of aripiprazole dimer on neuroplasticity and synaptic function may provide insights into its long-term therapeutic effects and potential neuroprotective properties.


The pharmacodynamic properties of aripiprazole dimer have important therapeutic implications for the treatment of psychiatric disorders. By targeting multiple neurotransmitter systems and modulating synaptic function, the compound offers a unique mechanism of action that may be beneficial for patients who do not respond adequately to traditional antipsychotic or antidepressant medications. Additionally, its partial agonist activity and receptor selectivity may contribute to a more favorable side effect profile compared to other antipsychotic agents, potentially improving patient tolerability and adherence to treatment regimens.


Preclinical studies play a crucial role in evaluating the pharmacological properties, efficacy, and safety profile of aripiprazole dimer before advancing to clinical trials. In vitro studies provide valuable insights into the compound’s receptor binding affinity, pharmacokinetics, and mechanism of action. Cell-based assays, receptor binding assays, and functional assays help elucidate the compound’s interactions with neurotransmitter receptors and downstream signaling pathways. Animal studies, including pharmacodynamic and pharmacokinetic experiments, assess the compound’s effects on behavior, neurochemistry, and physiological parameters. These studies provide essential data to guide dose selection, formulation development, and study design for subsequent clinical trials.


Clinical trials are conducted to evaluate the safety, efficacy, and tolerability of aripiprazole dimer in human subjects across different psychiatric indications. Phase I trials assess the compound’s pharmacokinetics, metabolism, and safety profile in healthy volunteers, providing initial data on dose-ranging and adverse effects. Phase II trials involve patients with specific psychiatric disorders, such as schizophrenia, bipolar disorder, or major depressive disorder, to assess the compound’s efficacy and optimal dosing regimen. These trials employ standardized rating scales and clinical assessments to measure symptom improvement and treatment response. Phase III trials involve larger patient populations and longer treatment durations to confirm the compound’s efficacy, safety, and tolerability in real-world clinical settings. These trials are essential for regulatory approval and market authorization.


Clinical trials provide evidence of aripiprazole dimer’s efficacy in reducing symptoms of psychosis, mania, depression, and agitation associated with various psychiatric disorders. The compound demonstrates comparable or superior efficacy to existing antipsychotic and antidepressant medications, with a lower risk of extrapyramidal symptoms and metabolic side effects. Common adverse effects include nausea, headache, insomnia, and akathisia, although these are generally mild to moderate in severity and transient in nature. Long-term studies assess the compound’s safety and tolerability over extended treatment durations, monitoring for potential adverse events such as weight gain, metabolic disturbances, and cardiovascular effects. Overall, clinical trials support the favorable efficacy and safety profile of aripiprazole dimer as a promising treatment option for patients with schizophrenia, bipolar disorder, and major depressive disorder.


Clinical trials also investigate the use of aripiprazole dimer in special populations, including pediatric patients, elderly individuals, and patients with comorbid medical conditions. Pediatric studies assess the compound’s safety and efficacy in children and adolescents with psychiatric disorders, providing evidence-based treatment recommendations for this vulnerable population. Geriatric studies evaluate the use of aripiprazole dimer in elderly patients, considering age-related changes in pharmacokinetics, comorbidities, and drug interactions. Studies in patients with hepatic or renal impairment assess the compound’s pharmacokinetics and dosing adjustments in individuals with impaired organ function. These studies contribute to personalized treatment strategies and ensure safe and effective use of aripiprazole dimer across diverse patient populations.


Preclinical and clinical studies provide essential data to support the development and clinical use of aripiprazole dimer as a novel treatment for psychiatric disorders. These studies demonstrate the compound’s efficacy, safety, and tolerability in reducing symptoms of psychosis, mood disturbances, and agitation across different patient populations. Continued research efforts aim to further elucidate the compound’s pharmacological mechanisms, optimize treatment strategies, and improve outcomes for patients with psychiatric conditions.

Leave a Reply

Your email address will not be published. Required fields are marked *